Search Results - "Link, James T"

Immunotherapy Progress in Mismatch Repair-Deficient Colorectal Cancer and Future Therapeutic Challenges by Link, James T, Overman, Michael James

“…Initial investigations of immune-checkpoint therapy targeting Programmed cell death protein 1/programed death ligand 1 in unselected colorectal cancer (CRC)…”
Get full text

The oncologic burden of hepatitis C virus infection: A clinical perspective by Torres, Harrys A., Shigle, Terri Lynn, Hammoudi, Nassim, Link, James T., Samaniego, Felipe, Kaseb, Ahmed, Mallet, Vincent

“…ABSTRACT Answer questions and earn CME/CNE Chronic hepatitis C virus (HCV) infection affects millions of people worldwide and is associated with cancer…”
Get full text

A stereoselective synthesis of indole-.beta.-N-glycosides: an application to the synthesis of rebeccamycin by Gallant, Michel, Link, James T, Danishefsky, Samuel J

Get full text

Discovery of Potent Antagonists of Leukocyte Function-Associated Antigen-1/Intercellular Adhesion Molecule-1 Interaction. 3. Amide (C-Ring) Structure−Activity Relationship and Improvement of Overall Properties of Arylthio Cinnamides by Pei, Zhonghua, Xin, Zhili, Liu, Gang, Li, Yihong, Reilly, Edward B, Lubbers, Nathan L, Huth, Jeffery R, Link, James T, von Geldern, Thomas W, Cox, Bryan F, Leitza, Sandra, Gao, Yi, Marsh, Kennan C, DeVries, Peter, Okasinski, Greg F

“…The interaction of LFA-1 and ICAM-1 plays an important role in the cell adhesion process. On the basis of previously reported SAR and structural information on…”
Get full text

Pharmacological regulation of hepatic glucose production by Link, James T

“…The discovery of antidiabetic agents that inhibit hepatic glucose production is a popular and potentially fruitful research area for the pharmaceutical…”
Get more information

Abstract 5678: Novel glucocorticoid receptor degrading bifunctional molecules as therapeutics in castration-resistant prostate cancer by Link, James T., Blazanin, Nicholas, Deribe, Yonathan Lissanu

“…Abstract While the majority of men with prostate cancer will experience modest morbidity, advanced castration-resistant prostate cancer (CRPC) remains a…”
Get full text

Biaryl amide glucagon receptor antagonists by KURUKULASURIYA, Ravi, SORENSEN, Bryan K, ADLER, Andrew L, COLLINS, Christine A, LINK, James T, PATEL, Jyoti R, JAE, Hwan-Soo, WINN, Marty X, ROHDE, Jeffrey R, GRIHALDE, Nelson D, LIN, Chun W, OGIELA, Christopher A

“…Biaryl amides derived from a reported series of ureas 1 were evaluated and found to be potent human glucagon receptor antagonists. The benzofuran analogue 6i…”
Get full text

Discovery and SAR of diarylsulfide cyclopropylamide LFA-1/ICAM-1 interaction antagonists by Link, James T., Sorensen, Bryan, Liu, Gang, Pei, Zhonghua, Reilly, Edward B., Leitza, Sandra, Okasinski, Greg

“…Diarylsulfide cyclopropylamides were synthesized and evaluated as LFA-1/ICAM-1 interaction antagonists. A substituent pattern was identified which maximized…”
Get full text

Liver-Selective Glucocorticoid Antagonists:  A Novel Treatment for Type 2 Diabetes by von Geldern, Thomas W, Tu, Noah, Kym, Philip R, Link, James T, Jae, Hwan-Soo, Lai, Chunqiu, Apelqvist, Theresa, Rhonnstad, Patrik, Hagberg, Lars, Koehler, Konrad, Grynfarb, Marlena, Goos-Nilsson, Annika, Sandberg, Johnny, Österlund, Marie, Barkhem, Tomas, Höglund, Marie, Wang, Jiahong, Fung, Steven, Wilcox, Denise, Nguyen, Phong, Jakob, Clarissa, Hutchins, Charles, Färnegårdh, Mathias, Kauppi, Björn, Öhman, Lars, Jacobson, Peer B

Get full text

Abstract 4672: Tumor dihydropyrimide dehydrogenase (DPYD) expression is associated with survival in patients with metastatic colorectal cancer treated with gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin (IFOX) by Francisco, Edgar B., Link, James T., Ramsey, Meghan, Beck, Andy H., Schwartz, Erich, Rouse, Robert, Fisher, George A., Sikic, Branimir I.

“…Abstract New drugs that target the EGFR signaling pathways suggest that EGFR inhibition exerts a chemosensitizing effect in colorectal cancer. We have…”
Get full text

Hepatic glucocorticoid receptor antagonism is sufficient to reduce elevated hepatic glucose output and improve glucose control in animal models of type 2 diabetes by Jacobson, Peer B, von Geldern, Thomas W, Ohman, Lars, Osterland, Marie, Wang, Jiahong, Zinker, Bradley, Wilcox, Denise, Nguyen, Phong T, Mika, Amanda, Fung, Steven, Fey, Thomas, Goos-Nilsson, Annika, Grynfarb, Marlena, Barkhem, Tomas, Marsh, Kennan, Beno, David W A, Nga-Nguyen, Bach, Kym, Philip R, Link, James T, Tu, Noah, Edgerton, Dale S, Cherrington, Alan, Efendic, Suad, Lane, Benjamin C, Opgenorth, Terry J

“…Glucocorticoids amplify endogenous glucose production in type 2 diabetes by increasing hepatic glucose output. Systemic glucocorticoid blockade lowers glucose…”
Get more information

Liver-Selective Glucocorticoid Antagonists:  A Novel Treatment for Type 2 Diabetes by von Geldern, Thomas W, Tu, Noah, Kym, Philip R, Link, James T, Jae, Hwan-Soo, Lai, Chunqiu, Apelqvist, Theresa, Rhonnstad, Patrik, Hagberg, Lars, Koehler, Konrad, Grynfarb, Marlena, Goos-Nilsson, Annika, Sandberg, Johnny, Österlund, Marie, Barkhem, Tomas, Höglund, Marie, Wang, Jiahong, Fung, Steven, Wilcox, Denise, Nguyen, Phong, Jakob, Clarissa, Hutchins, Charles, Färnegårdh, Mathias, Kauppi, Björn, Öhman, Lars, Jacobson, Peer B

“…Hepatic blockade of glucocorticoid receptors (GR) suppresses glucose production and thus decreases circulating glucose levels, but systemic glucocorticoid…”
Get full text